BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 1,091 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the sale, the insider now directly owns 58,816 shares of the company's stock, valued at approximately $1,470,400. This trade represents a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Sarah Aebersold also recently made the following trade(s):
NASDAQ BLFS traded down $1.21 during trading hours on Thursday, reaching $25.06. The company's stock had a trading volume of 278,326 shares, compared to its average volume of 349,466. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The firm's 50-day moving average price is $26.64 and its 200-day moving average price is $25.51. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the previous year, the company posted ($0.21) EPS. On average, equities research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.
A number of analysts recently commented on the company. HC Wainwright raised their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. Benchmark restated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.86.
Get Our Latest Analysis on BioLife Solutions
Several hedge funds have recently bought and sold shares of BLFS. Raymond James Financial Inc. purchased a new stake in shares of BioLife Solutions in the 4th quarter worth $20,664,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of BioLife Solutions during the 4th quarter worth $19,805,000. Point72 Asset Management L.P. purchased a new stake in shares of BioLife Solutions during the 4th quarter worth $11,113,000. Millennium Management LLC lifted its stake in shares of BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock worth $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock worth $14,661,000 after purchasing an additional 262,504 shares during the last quarter. Institutional investors own 93.24% of the company's stock.
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.